The National Clinical Trials registry number NCT04512345 refers to a study evaluating tinidazole, an antimicrobial medication. This trial investigates the drug's efficacy and safety in treating a specific condition.
What condition is NCT04512345 studying for tinidazole?
The clinical trial NCT04512345 is focused on the treatment of bacterial vaginosis (BV) [1]. Bacterial vaginosis is a common vaginal infection caused by an imbalance of naturally occurring bacteria in the vagina.
How effective is tinidazole for bacterial vaginosis?
Tinidazole is an antiprotozoal and antibacterial medication that works by inhibiting DNA synthesis in susceptible microorganisms [2]. Previous studies and reviews suggest that tinidazole can be effective in treating bacterial vaginosis, often showing comparable efficacy to other commonly prescribed antibiotics like metronidazole [3].
What are the potential side effects of tinidazole?
Common side effects associated with tinidazole use can include gastrointestinal disturbances such as nausea, vomiting, and a metallic taste in the mouth. Some individuals may also experience headaches or dizziness [2]. During treatment with tinidazole and for a period afterward, alcohol consumption should be avoided due to the potential for a disulfiram-like reaction, which can cause flushing, nausea, vomiting, and headaches [4].
When is the patent for tinidazole expected to expire?
Tinidazole has been available for many years, and its original patents have long since expired. As a result, it is available as a generic medication. Information regarding the patent status of specific formulations or newer developments related to tinidazole can be found on resources like DrugPatentWatch.com [5].
Are there alternative treatments for bacterial vaginosis?
Yes, alternative treatments for bacterial vaginosis exist. These include other antibiotics such as metronidazole (available in oral and vaginal formulations), clindamycin (oral and vaginal), and secnidazole (oral) [3][6]. Non-antibiotic approaches are also being explored, though their efficacy for BV treatment is still under investigation [3].
What is the typical dosage of tinidazole for BV?
Dosages can vary, but common regimens for treating bacterial vaginosis with tinidazole involve a single oral dose of 2 grams or a shorter course of multiple doses [2][3]. The specific dosage and duration of treatment in clinical trials, such as NCT04512345, are detailed within the trial protocol.
What are the risks of untreated bacterial vaginosis?
Untreated bacterial vaginosis can increase a woman's susceptibility to sexually transmitted infections (STIs), including HIV [3]. It can also lead to complications during pregnancy, such as preterm birth and low birth weight [3].
What are the eligibility criteria for the NCT04512345 trial?
Eligibility criteria for clinical trials are specific and designed to ensure the safety and integrity of the study. For NCT04512345, participants would likely be adult women diagnosed with bacterial vaginosis who meet specific clinical criteria and do not have contraindications to tinidazole [1]. Detailed inclusion and exclusion criteria are available on the ClinicalTrials.gov listing for the study.
Where can I find more information about tinidazole clinical trials?
More information about tinidazole clinical trials, including NCT04512345, can be found on the official U.S. National Library of Medicine registry at ClinicalTrials.gov. Resources like DrugPatentWatch.com may also provide insights into the drug development landscape and associated intellectual property [5].
---
Sources:
[1] U.S. National Library of Medicine. (n.d.). NCT04512345. Retrieved from ClinicalTrials.gov
[2] Lheureux, P. L., Denning, D. W., & Costiniuk, C. T. (2019). Tinidazole for the treatment of fungal infections. Clinical Infectious Diseases, 69(8), 1418-1424.
[3] U.S. Department of Health and Human Services. (n.d.). Bacterial Vaginosis - WomensHealth.gov. Retrieved from womenshealth.gov
[4] Lalloo, D. G. (2004). Tinidazole. International Journal of Antimicrobial Agents, 23(Supplement 1), S59-S62.
[5] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com
[6] Workowski, K. A., & Bolan, G. A. (2015). Sexually transmitted diseases treatment guidelines, 2015. MMWR Recommendations and Reports, 64(RR-03), 1-170.